

Table of Content

INTRODUCTION	1
CHAPTER 1	
1.1 Introduction	4
1.1.1 The protein SARM1: the fifth member of the TLR adaptor protein	4
1.1.2 TIR domain of SARM1 and NADase activity	7
1.1.3 Regulation of programmed axonal degeneration by SARM1	8
1.1.4 SARM1 in the mitochondria	11
1.1.5 Role of ETC complex proteins in neurodegeneration	12
1.1.6 Concluding remarks	13
1.2 Materials and Method	13
1.2.1 <i>In silico</i> analysis	13
1.2.1.1 Retrieving the protein sequences	13
1.2.1.2 Multiple sequence alignment	14
1.2.1.3 Secondary structure prediction	14
1.2.1.4 Homology modelling	14
1.2.1.5 Comparison of protein structures	14
1.2.1.6 Prediction of binding site	14
1.2.1.7 Prediction of nuclear export signal (NES)	15
1.2.2 <i>In vitro</i> studies	15
1.2.2.1 Generation of deletion mutants	15
1.2.2.2 Isolation of plasmid DNA	17
1.2.2.3 Agarose gel electrophoresis	18
1.2.2.4 Polymerase Chain Reaction (PCR)	19
1.2.2.5 DNA extraction from agarose gel	19
1.2.2.6 Recombinant DNA techniques	20
1.2.3 Cell culture	22
1.2.4 Real-Time PCR	24
1.2.5 Immunoblot experiments	26

1.2.6 Isolation of mitochondrial fraction	29
1.2.7 Isolation of nuclear fraction	30
1.2.8 Immunocytochemistry	30
1.2.9 Mitochondrial staining	31
1.2.10 Transfection of cells	31
1.2.11 Measurement of intracellular NAD ⁺ level	32
1.3 Results	32
1.3.1 <i>In silico</i> analysis of SARM1	32
1.3.1.1 TIR domain of SARM1 is responsible for the opposite functional roles of <i>C.elegans</i> and human SARM1	32
1.3.1.2 Human SARM1 TIR is closer to bacterial TcpB TIR compared to other human adaptor TIRs	34
1.3.1.3 SAM domain of human SARM1 may bind macromolecules like DNA or RNA and it possesses nuclear export signal (NES)	37
1.3.2 Evaluating the role of endogenous SARM1 in mitochondrial homeostasis	38
1.3.2.1 The mitochondrial complex I inhibitor rotenone induces cell death in a dose and time-dependent manner in SH-SY5Y cells	38
1.3.2.2 Rotenone treatment results in mitochondrial damage in SH-SY5Y cells	39
1.3.2.3 Rotenone treatment induces <i>Sarm1</i> expression and is required for rotenone induced cell death in SH-SY5Y cells	40
1.3.2.4 Rotenone treatment results in de-regulation of ETC complex genes in SH-SY5Y cells	42
1.3.2.5 Rotenone mediated cell death and SARM1 induction is reversed in the presence of NR, a precursor of NAD ⁺	43
1.3.2.6 Rotenone induced de-regulation of the respiratory complex genes is partially reversed in the presence of NR	44
1.3.2.7 Rotenone increases <i>Sirtuin</i> gene expression that is reversed in NR treated cells	45
1.3.2.8 Rotenone induced cell death and SARM1 induction is partially reversed in the presence of calcium channel blockers	46

1.3.2.9 Rotenone induced de-regulation of the respiratory complex genes is partially reversed in the presence of nimodipine	48
1.3.3 SARM1 overexpression studies in SH-SY5Y and HEK293 cells	49
1.3.3.1 Overexpression of SARM1 and its mutants leads to cell death in SH-SY5Y cells	49
1.3.3.2 Overexpression of SARM1 and its mutants results in de-regulation of ETC complex genes distinct from endogenous SARM1	50
1.4 Discussion	51
CHAPTER 2	
2.1. Introduction	54
2.1.1. Oxidative stress in neurodegenerative diseases	54
2.1.2. Site of ROS generation	55
2.1.3. SARM1 and ROS: a perspective	56
2.1.4. SARM1 in cell death regulation	57
2.1.5. Calcium flux in neurodegeneration	59
2.1.6. Inflammatory response in neurodegenerative diseases: Does SARM1 play role?	60
2.1.7. Concluding remarks	62
2.2. Materials and Methods	66
2.2.1. Cell culture	66
2.2.2. Real-Time PCR	66
2.2.3. Immunoblot experiments	66
2.2.4. Immunocytochemistry	66
2.2.5. ROS assay	67
2.2.6. Detection of mitochondrial superoxide generation	67
2.2.7. Blocking of TNF α in SH-SY5Y cells	67
2.2.8 Mitochondrial and lysosomal staining	67
2.3. Results	68
2.3.1. Studying the effect of rotenone mediated ROS generation in SARM1 induction	68
2.3.1.1. Rotenone treatment in SH-SY5Y cells is accompanied by increased ROS generation and antioxidant responses	68

2.3.1.2. Other mitochondrial complex inhibitors also induce cell death and ROS generation in SH-SY5Y cells	69
2.3.1.3. SARM1 is not induced in the presence of other mitochondrial complex inhibitors	70
2.3.1.4. Overexpression of SARM1 and its mutants do not accumulate ROS in SH-SY5Y cells	72
2.3.2. Regulation of rotenone induced autophagic pathway and its effect on SARM1	73
2.3.2.1. Rotenone inhibits autophagic flux that may result in SARM1 induction in SH-SY5Y cells	73
2.3.2.2. NR partially reverses rotenone induced de-regulation of autophagy genes in SH-SY5Y cells	77
2.3.2.3. The autophagy inhibitor bafilomycin reversed rotenone induced cell death and prevents SARM1 induction in SH-SY5Y cells	78
2.3.2.4. Rotenone treatment blocked mitophagy in HEK293 cells.	78
2.3.3. Inflammatory responses within the neuronal cells might trigger SARM1 activation SH-SY5Y cells	79
2.4. Discussion	81
 CHAPTER 3	
3.1. Introduction	84
3.1.1. Aging and neurodegeneration	84
3.1.2. Environmental toxin induced neurodegeneration	86
3.1.3. Drosophila: an ideal genetic tool for studying age-associated neurodegeneration	88
3.1.4. Mitochondrial complex I inhibitor rotenone and ROS production	89
3.1.5. Mitochondrial dysfunction and Parkinson's disease	90
3.1.6. Neuroinflammatory responses in experimental models of PD	91
3.1.7. Concluding remarks	91
3.2. Materials and Methods	91
3.2.1. Fly strains	91
3.2.2. Fly exposures	92
3.2.3. Fly survival assay	93
3.2.4 Negative geotaxis assay	93

3.2.5. Whole brain mount immunofluorescence labelling	93
3.2.6. Real-Time PCR	93
3.2.7. Measurement of ROS generation	95
3.2.8. Western blot analysis	95
3.2.9. Mathematical modelling	96
3.2.10 Statistical analysis	98
3.3. Results	98
3.3.1. Rotenone mediates decreased lifespan and progressive locomotor deficits in an age-dependent manner in w ¹¹¹⁸ strain of <i>Drosophila</i>	98
3.3.2. Rotenone induced locomotor deficit is accompanied by increased <i>dSarm</i> expression	100
3.3.3. An early induction of dSarm was necessary and sufficient for rotenone induced neurotoxicity	102
3.3.4. Rotenone mediated neurotoxicity is independent of ROS generation	104
3.3.5. Rotenone induced locomotor deficits was accompanied by increased <i>PINK1</i> expression and reduction of autophagic flux	105
3.3.6. Rotenone exposure mediates decreased learning ability and synaptic deregulation in w ¹¹¹⁸ strain of <i>Drosophila</i>	106
3.3.7. Rotenone exposure in w ¹¹¹⁸ flies causes increased expression of stress related genes	107
3.3.8. Age-mediated heightened susceptibility to rotenone was associated with increased inflammatory response	108
3.3.9. The anti-inflammatory molecule resveratrol rescued rotenone-mediated locomotor defects and reduced <i>dSarm</i> Expression	110
3.3.10. The NAD ⁺ precursor Nicotinamide riboside (NR), rescued rotenone induced loss of survival and associated motor deficits	112
3.4. Discussion	116
CONCLUSION	119
REFERENCES	122
APPENDIX	147

Table of Abbreviations

Symbol	Definition
a-a	Amino acid
ACT	Actin
AD	Alzheimer's disease
ADPR	ADP-ribose
AMBRA	Autophagy and Beclin 1 Regulator
AMPK	AMP-activated protein kinase
ANOVA	Analysis of variance
APP	Amyloid precursor protein
ARE	Antioxidant response element
ARM	Armadillo
As	Arsenite
Atg	Autophagy
ATP	<i>Adenosine triphosphate</i>
BAD	BCL2 Associated Agonist of Cell Death
BAK	Bcl-2 homologous antagonist/killer
Bax	BCL2 Associated X
BBB	Blood brain barrier
BECN	Beclin
BN-PAGE	Blue native polyacrylamide gel electrophoresis
BSA	Bovine serum albumin
C.elegans	<i>Caenorhabditis elegans</i>
cADPR	Cyclic ADP-ribose
CaM kinase	Ca ²⁺ /calmodulin-dependent protein kinase
CaMKI	Calcium/Calmodulin Dependent Protein Kinase I
CAMP	Compound muscle action potentials
cAMP	3',5'-cyclic adenosine monophosphate

Symbol	Definition
CCCP	Carbonyl cyanide m-chlorophenyl hydrazone
CCL5	C-C Motif Chemokine Ligand 5
cDNA	Complementary DNA
CFSSP	Chou & Fasman Secondary Structure Prediction Server
CNS	Central nervous system
COX5	Cytochrome c oxidase subunit V
cryo-EM	Cryo-electron microscopy
CT	Threshold cycle
CYC	Cytochrome C
DA	Dopamine
DAMPS	Damage associated molecular patterns
DAPI	4',6-diamidino-2-phenylindole
DCFDA	2',7' -dichlorofluorescein diacetate
DMEM	Dulbecco's Modified Eagle Medium
DMSO	Dimethyl sulfoxide
DNA	Deoxyribonucleic acid
DRAM	DNA Damage Regulated Autophagy Modulator
DRG	Dorsal root ganglia
<i>E.coli</i>	<i>Escherichia coli</i>
EAAT-1	Excitatory amino acid transporter 1
ECL	Enhanced chemiluminescence
ECT4	Ectoderm-expressed 4
EDTA	Ethylenediaminetetraacetic acid
EGTA	Ethylene glycol tetraacid acid
ELAV	Embryonic lethal abnormal visual system
ETC	Electron transport chain
FBS	Foetal bovine serum
FCCP	Carbonyl cyanide p-(trifluoromethoxy)

Symbol	Definition
	phenylhydrazone
Fer-1	ferrostatin-1
FITC	Fluorescein isothiocyanate
FMN	Flavin mono nucleotide
GABARAP	GABA Type A Receptor-Associated Protein
GAPDH	Glyceraldehyde 3-phosphate dehydrogenase
GFP	Green <i>fluorescent protein</i>
GPX	<i>Glutathione peroxidase</i>
HD	Huntington's disease
HRP	Horse Radish Peroxidase
Hsp	Heat shock protein
IgG	Immunoglobulin G
IL	Interleukin
IMM	Inner mitochondrial membrane
IRF	Interferon regulatory factors
IRGM	Immunity Related GTPase M
JAK-STAT	Janus kinase/signal transducers and activators of transcription
JNK	c-Jun N-terminal kinase
KO	Knock out
LA	Luria agar
LACV	La Crosse virus
LB	Luria broth
LC3B	Microtubule-associated proteins 1A/1B light chain 3B
L-DOPA	l-3,4-dihydroxyphenylalanine
mA	Milliampere
MAL	MyD88 adaptor-like
MAP1LC3	Microtubule Associated Protein 1 Light

Symbol	Definition
	Chain 3
MAP2	Microtubule-associated protein 2
MAPK	Mitogen-activated protein kinase
MAVS	Mitochondrial antiviral signaling protein
Mir	microRNA
MLS	Mitochondrial localization signal
M-PER	Mammalian protein extraction reagent
MPTP	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
mRNA	Messenger RNA
mROS	Mitochondrial reactive oxygen species
MS	Multiple sclerosis
MTT	3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
MyD88	Myeloid differentiation primary response 88
NAADP	Nicotinic acid adenine dinucleotide phosphate
NAC	N-acetyl cysteine
nAChRbeta	Nicotinic acetylcholine receptor beta 2
NAD	Nicotinamide adenine dinucleotide
NCBI	National Center for Biotechnology Information
NDS	Normal donkey serum
Ndufs	NADH-ubiquinone oxidoreductase
NES	Nuclear export signal
NF-κB	Nuclear factor-κB
NGF	Nerve growth factor
NLS	Nuclear localization signal
NMN	Nicotinamide mononucleotide
NMNAT	Nicotinamide-nucleotide

Symbol	Definition
	adenylyltransferase
NR	Nicotinamide riboside
NRF	Nuclear respiratory factor
NRK	Nicotinamide riboside kinases
Nrx-1	Neurexin 1
OD	Optical density
ORF	Open reading frame
OS	Oxidative stress
PAGE	Polyacrylamide gel electrophoresis
PAMP	Pathogen associated molecular patterns
PARP	Poly (ADP-Ribose) Polymerase
PBS	Phosphate-buffered saline
PBST	Phosphate-buffered saline with Tween 20
PCR	Polymerase chain reaction
PD	Parkinson's disease
PFA	Para formaldehyde
PINK1	PTEN-induced putative kinase 1
PRR	Pattern recognition receptors
PTGS	<i>Prostaglandin-Endoperoxide Synthase</i>
qPCR	Quantitative polymerase chain reaction
RMSD	Root mean square deviation
RNA	Ribonucleic acid
RNAi	RNA interference
ROS	Reactive oxygen species
rpm	Rotation per minute
RT	Room temperature
RT-PCR	Reverse transcription polymerase chain reaction
SAM	Sterile alpha motif
SARM1	Sterile Alpha And TIR Motif Containing 1

Symbol	Definition
SCG	Superior cervical ganglia
SCs	Supercomplexes
SDS	Sodium dodecyl sulphate
SEM	Standard error of mean
siRNA	Small interfering Ribonucleic Acid
SIRT	Sirtuin
TAE	Tris acetate EDTA
TBS	<i>Tris-buffered saline</i>
TBST	Tris-buffered saline with Tween 20
Tcp	TIR domain containing protein
TEMED	N, N, N', N'-tetramethyl ethylene
TEP	Telomerase Associated Protein
TH	Tyrosine hydroxylase
TIR	Toll/interleukin-1 receptor
Tir-1	Transport inhibitor response 1
TLR	Toll like receptor
TNF α	<i>Tumor necrosis factor</i>
TOT	Turandot
TRAF	TNF receptor associated factor
TRAM	Translocating Chain-Associated Membrane
TRIF	TIR-domain-containing adapter-inducing interferon- β
ube4B	Ubiquitin conjugation factor E4B
UTR	Untranslated region
UV	Ultraviolet
WD	Wallerian degeneration
Wld ^s	Slow Wallerian degeneration protein
WT	Wild type

Table of Figures

Fig. 1.	World map of prevalence of Parkinson's disease	2
Fig. 2.	TLR signalling involves a family of five adaptor proteins	5
Fig. 3.	Protein sequence of SARM1 indicating its functional domains; MLS (Mitochondrial localization signal), ARM (Armadillo), SAM1 and SAM2 (Sterile α motif), TIR (Toll/interleukin-1 receptor)	6
Fig. 4.	TIR domain of SARM1 has NADase activity that cleaves NAD ⁺ into nicotinamide	8
Fig. 5.	Wallerian degeneration: After an axonal lesion, the segment distal to the cut undergoes fragmentation before it entirely disintegrates within three days. Loss of dSarm or overexpression of Wld ^s in neurons keeps the distal axon intact even 14 days after the lesion. Adapted from Yu et al (Yu and Luo, 2012)	10
Fig. 6.	Deletion mutants of SARM1 generated	16
Fig. 7.	Physical map of pCMV6 vector used for cloning SARM1 mutants	17
Fig. 8.	Chemical structures of (A) Rotenone (B) Nimodipine (C) Nicotinamide Riboside (NR) and (D) EGTA	23
Fig. 9.	Standard curve of BSA	27
Fig. 10.	Tertiary structure prediction of (A) SAM1 (B) SAM2 (C) TIR domain of <i>C.elegans</i> SARM1 and (D) SAM1, (E) SAM2 (F) TIR domain of <i>H.sapiens</i> SARM1	33
Fig. 11.	Multalin comparison of SARM1 TIR with TIR domain of (A) <i>Brucella ovis</i> Tcp, (B) TRAM, (C) TRIF, (D) MyD88 and (E) MAL. (F) Graphical representation of sequence comparison of TIR of Tcp, TRAM, TRIF, MyD88 and MAL with SARM1	35
Fig. 12.	Multalin comparison of TIR domain of <i>Brucella ovis</i> Tcp with (A) TRAM, (B) TRIF, (C) MyD88 and (D) MAL. (E) Graphical Representation of sequence comparison of TIR of TRAM, TRIF, MyD88, MAL and SARM1 with Tcp	36
Fig. 13.	Secondary structure prediction of TIR domain of (A) Tcp, (B) SARM1, (C) MyD88, (D) TRAM, (E) MAL and (F) TRIF	36
Fig. 14.	Tertiary structure prediction of TIR domain of (A) SARM1, (B) MyD88, (C) TRAM, (D) MAL and (E) TRIF	37
Fig. 15.	Prediction of DNA binding site in SARM1 protein sequence as shown by proNA	38

- Fig. 16.** Prediction of nuclear export signal (NES) in SARM1 protein sequence as shown by NetNES 1.1 online server 38
- Fig. 17.** Rotenone treatment in SH-SY5Y cells (A, B) Immunofluorescence analysis of SH-SY5Y cells treated with 5 μ M of rotenone for 24 h (B) and compared to untreated control cells (A). Tubulin staining of both the treated and untreated samples are shown. Scale bars = 10 μ m (C) MTT assay of SH-SY5Y cells treated with rotenone (2.5 and 5 μ M) for 24 and 48 h. Results are representative of at least five independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample 39
- Fig. 18.** Rotenone treatment in SH-SY5Y and HEK293 cells; (A) labelling of mitochondria using MitoTracker Green in SH-SY5Y cells showed a reduction in rotenone treated cells, compared to control (B) HEK293 cells treated with TMRM dye showed a reduction in mitochondrial potential in rotenone treated cells, compared to control. Scale bars = 10 μ m 40
- Fig. 19.** Real time PCR analysis of SH-SY5Y cells treated with 2.5 and 5 μ M of rotenone for 24 h (A) Expression of *Sarm1* from whole cell extracts. (B) Analysis of SARM1 protein levels in the nuclear and mitochondrial fractions of rotenone (5 μ M) treated SH-SY5Y cells. Lamin and COX IV were used as loading control for the nuclear and mitochondrial fraction respectively. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample 41
- Fig. 20.** SH-SY5Y cells were treated with 25 nM of SARM1 siRNA or control (nontargeting) siRNA for 24 h followed by 5 μ M of rotenone treatment for 24 h. (A) MTT assay of cells treated with rotenone in the presence or absence of siRNAs was performed. (B) Analysis of SARM1 protein levels in the whole cell extracts of cells transfected with SARM1 or control siRNA in the presence or absence of rotenone (5 μ M). β -actin was used as a loading control. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample 41
- Fig. 21.** Real-time PCR analysis of SH-SY5Y cells treated with 2.5 and 5 μ M of rotenone for 24 h. Expression of ETC complex genes from whole cell extracts were analysed. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control samples 42

- Fig. 22.** Real-time PCR analysis of SH-SY5Y cells treated with 25 nM of SARM1 siRNA or control (nontargeting) siRNA for 24 h followed by 5 μ M of rotenone treatment for 24 h. (A, B) Expression of ETC complex genes from whole cell extracts were analysed. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control samples 43
- Fig. 23.** SH-SY5Y cells were treated with rotenone along with NR. (A) NAD⁺ levels detection assay of SH-SY5Y cells treated with 5 μ M of rotenone for 24 h. (B) MTT assay of cells treated with rotenone (5 μ M) and NR (0.5 mM) for 24 h. (C) Real-time PCR analysis of SH-SY5Y cells treated with rotenone (5 μ M) and NR (0.5 mM) for 24 h. Expression of *Sarm1* from whole cell extracts was analysed. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample 44
- Fig. 24.** Real-time PCR analysis of SH-SY5Y cells treated with rotenone (5 μ M) and NR (0.5 mM) for 24 h. Expression of ETC complex genes from whole cell extracts were analysed. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample 45
- Fig. 25.** Real-time PCR analysis of SH-SY5Y cells treated with rotenone (5 μ M) and NR (0.5 mM) for 24 h. Expression of *Sirtuin* genes from whole cell extracts were analysed. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample 46
- Fig. 26.** SH-SY5Y cells were treated with rotenone along with nimodipine. (A) Axonal retraction of SH-SY5Y cells treated with 5 μ M of rotenone and 10 μ M of nimodipine for 24 h. (B) Real-time PCR analysis of SH-SY5Y cells treated with rotenone (5 μ M) and nimodipine (10 μ M) for 24 h. Expression of *Sarm1* from whole cell extracts was analysed. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample 47
- Fig. 27.** SH-SY5Y cells were treated with rotenone along with EGTA. (A) Real-time PCR analysis of SH-SY5Y cells treated with rotenone (5 μ M) and EGTA (2.5 mM) for 24 h. Expression of *Sarm1* from whole cell extracts was analysed. (B) Axonal retraction of SH-SY5Y cells treated with 5 μ M of rotenone and 2.5 mM of EGTA for 24 h. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample 48

- Fig. 28.** Real-time PCR analysis of SH-SY5Y cells treated with rotenone (5 μ M) and nimodipine (10 μ M) for 24 h. Expression of ETC complex genes from whole cell extracts was analysed. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample 48
- Fig. 29.** Deletion mutants of SARM1 cloned in pCMV6 vector. Vectors were digested by restriction endonucleases (EcoRI and XhoI) and base pair length of each SARM1 mutants were compared with the respective ladder size 49
- Fig. 30.** SH-SY5Y cells were overexpressed with SARM1 (A) Immunofluorescence analysis of SH-SY5Y cells overexpressed with different SARM1 deletion mutants for 24 h and compared to non-transfected control cells. DAPI (blue) and MAP2 (green) staining of both the transfected and non-transfected samples are shown. (B) MTT assay of cells overexpressed with different SARM1 deletion mutants for 48 h was performed. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control samples 50
- Fig. 31.** Real-time PCR analysis of SH-SY5Y cells overexpressed with different SARM1 deletion mutants and non-transfected cells. Expression of ETC complex genes from whole cell extracts were analysed. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control samples 51
- Fig. 32.** Relationship between microglial activation and neuronal death. Neurotoxins may induce microglial activation that favours neuroinflammation, leading to neuronal death 55
- Fig. 33.** SARM1 has been implicated in ROS generation, mitophagy, autophagy and apoptosis. Although, whether SARM1 is a central molecule of these pathways is yet to be explored 62
- Fig. 34.** Chemical structure of (A) FCCP, (B) Oligomycin, (C) Bafilomycin (D) Resveratrol (E) Antimycin (F) Chloroquine and (G) NAC 63
- Fig. 35.** SH-SY5Y cells were treated with rotenone along with NAC (A) ROS generation assay of SH-SY5Y cells treated with 2.5 and 5 μ M of rotenone for 3 and 4 h (B) Mitosox staining analysis of SH-SY5Y cells treated with 5 μ M of rotenone (C) ROS generation assay of SH-SY5Y cells treated with 5 μ M of rotenone and 5 μ M of NAC (D) Axonal retraction of SH-SY5Y cells treated with 5 μ M of rotenone and 5 μ M of NAC for 24 h. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample 68

- Fig. 36.** SH-SY5Y cells were treated with rotenone (A, B) Real-time PCR analysis of SH-SY5Y cells treated with 5 μ M of rotenone for 24 h. Expression of antioxidant genes from whole cell extracts were analysed 69
- Fig. 37.** MTT assay of cells treated with (A) antimycin (5 μ M) (B) oligomycin (10 μ M) and (C) FCCP (2 μ M) for 24 h. (D-G) Immunofluorescence analysis of SH-SY5Y cells treated with 5 μ M of antimycin, 10 μ M of oligomycin and 2 μ M of FCCP for 24 h and compared to untreated control cells. DAPI staining of both the treated and untreated samples are shown. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample 70
- Fig. 38.** ROS generation assay of cells treated with (A) antimycin (5 μ M) and (B) oligomycin (10 μ M) for 6 h. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample 70
- Fig. 39.** Real-time PCR analysis of SH-SY5Y cells treated with antimycin (5 μ M) and oligomycin (10 μ M) for 24 h. Expression of *Sarm1* from whole cell extracts were analysed. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample 71
- Fig. 40.** Real-time PCR analysis of SH-SY5Y cells treated with antimycin (5 μ M) and oligomycin (10 μ M) for 24 h. Expression of ETC complex genes from whole cell extracts were analysed. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample 71
- Fig. 41.** ROS generation assay of cells transfected with different deletion mutants of SARM1. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample 72
- Fig. 42.** Mitosox staining analysis of SH-SY5Y cells transfected with different deletion mutants of SARM1. Scale bars = 25 μ m 72
- Fig. 43.** Heat map presentation of the Q-PCR analysis of SH-SY5Y cells treated with rotenone (5 μ M). Autophagy related genes were analysed following 3 h, 6 h and 24 h post treatment. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample 74
- Fig. 44.** SH-SY5Y cells were treated with rotenone (A) Analysis of p62, ATG7 and LC3B protein levels in the whole cell extracts of cells treated with rotenone (5 μ M) at 24 h. β -actin was used as a loading control. (B) Quantification of LC3II/LC3I was done to determine

the LC3B concentration in control vs treated cells (C) Immunofluorescence analysis of SH-SY5Y cells treated with 5 μ M of rotenone for 24 h and compared to untreated control cells. DAPI (blue) tubulin (green) and p62 (red) staining of both the treated and untreated samples are shown. Scale bars = 10 μ m

75

Fig. 45. SH-SY5Y cells were treated with rotenone along with chloroquine (A) Immunofluorescence analysis of SH-SY5Y cells treated with 5 μ M of rotenone and chloroquine (100 μ M) for 24 h and compared to untreated control cells. DAPI (blue) and MAP2 (green) staining of both the treated and untreated samples are shown. Scale bars = 25 μ m (B) Real-time PCR analysis of SH-SY5Y cells treated with rotenone (5 μ M) and chloroquine (100 μ M) for 24 h. Expression of *Sarm1* from whole cell extracts were analysed. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample

76

Fig. 46. SH-SY5Y cells were treated with rotenone. (A, B) Immunofluorescence analysis of SH-SY5Y cells treated with 5 μ M of rotenone (B) for 24 h and compared to untreated control cells (A). DAPI (blue) and caspase-3 (red) staining of both the treated and untreated samples are shown. Scale bars = 5 μ m

76

Fig. 47. Real-time PCR analysis of SH-SY5Y cells treated with rotenone (5 μ M) and NR (0.5 mM). Autophagy related genes were analysed following 24 h post treatment. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample

77

Fig. 48. SH-SY5Y cells were treated with rotenone along with bafilomycin (A) Immunofluorescence analysis of SH-SY5Y cells treated with 5 μ M of rotenone and bafilomycin (100 nM) for 24 h and compared to untreated control cells. DAPI (blue) and MAP2 (green) staining of both the treated and untreated samples are shown. Scale bars = 25 μ m (B) Real-time PCR analysis of SH-SY5Y cells treated with rotenone (5 μ M) and bafilomycin (100 nM) for 24 h. Expression of *Sarm1* from whole cell extracts were analysed. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample

78

Fig. 49. HEK293 cells were treated with rotenone. (A, B) Immunofluorescence analysis of HEK293 cells treated with 500 nM of rotenone (B) for 24 h and compared to untreated control cells (A). Mitotracker green and LysoTracker red staining of both the treated and untreated samples are shown. Scale bars = 10 μ m

79

- Fig. 50.** SH-SY5Y cells were treated with rotenone. (A-C) Real-time PCR analysis of cells as treated with rotenone (5 μ M). *TNF α* (A), *IL1 β* (B) and *IL6* (C) genes was analysed following 24 h post-treatment 80
- Fig. 51.** SH-SY5Y cells were treated with rotenone along with resveratrol (A, B) Real-time PCR analysis of cells as treated with rotenone (5 μ M) in the presence or absence of resveratrol (5 or 20 μ M as indicated). *TNF α* (A) and *Sarm1* (B) genes were analysed following 6 h post-treatment. (C-E) SH-SY5Y cells were treated with rotenone along with TNF α blocker. Real-time PCR analysis of cells treated with rotenone (5 μ M) in the presence or absence of neutralizing antibody against TNF α (5 mg/ml). The expression of both *TNF α* (C) and *Sarm1* (D) were analysed following 24 h post-treatment. (E) MTT assay of cells treated with rotenone (5 μ M) in the presence or absence of neutralizing antibody against TNF α (5 mg/ml) for 24 h. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample 80
- Fig. 52.** Pesticide exposure in agricultural fields may induce risk of sporadic PD that is associated with axonal degeneration and broken synaptic connections in the dopaminergic neurons 86
- Fig. 53.** Chemical structure of Sodium arsenite 92
- Fig. 54.** (A) Schematic representation of rotenone treatment in the 1-day old flies for survival curve assay. (B) Survival curve of 1-day old flies exposed to varying concentration of rotenone (50, 100, and 200 μ M). Fly viability was scored over a period of 40-days using a minimum of 100 flies per treatment. The statistical significance was calculated as log-rank using Mantel–Cox test. (C–E) Negative geotaxis assay of 1-day old flies exposed to rotenone at concentrations indicated above for 1-day (C), 10-days (D) and 20-days (E). * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control flies 99
- Fig. 55.** (A) Schematic representation of rotenone treatment in the 1-day, 10-day, and 20-day old flies for survival curve assay. (B) Age-dependent survival of flies exposed to 100 μ M of rotenone at 1-day, 10-day, and 20-day following eclosion. Fly viability was scored up to 40-days, post-eclosion using a minimum of 100 flies per treatment. (C) Negative geotaxis assay of 20-day old flies exposed to 200 μ M rotenone for 3-days. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control flies 100

- Fig. 56.** (A) Schematic representation of experimental setup for rotenone treatment in the aged (20-days old) flies. (B, C) Expression of *dSarm* in young flies (1-day old) exposed to 200 μ M of rotenone for 1-day, 10-days, 20-days, and 30-days (B) and aged flies (20-days old) to 200 μ M of rotenone for 3-days and 5-days post-treatment (n = 5) (C). *p < 0.05, **p < 0.01, and ***p < 0.001 compared to control flies 101
- Fig. 57.** (A) Multifocal confocal image of dopaminergic neurons following tyrosine hydroxylase (TH) immunostaining (green) and Elav immunostaining (red) in the brains of flies exposed to 200 μ M rotenone at 20-days post-eclosion for 3-days (right-hand panel). Results were compared to age-matched rotenone untreated flies (left-hand panel). Scale bars = 200 μ m. (B) Bar graph represents the number of dopaminergic neuron cell bodies in the control and rotenone (200 μ M) treated fly brains (n = 3). (C) Representative western blot analysis of the dopaminergic neuronal marker tyrosine hydroxylase in 20-day old flies exposed to 200 μ M rotenone and analysed at day-3 post-exposure. β -actin served as a loading control and data was compared with age-matched untreated control flies (n = 3). Results are representative of at least three independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 compared to control sample 102
- Fig. 58.** (A-C) Mathematical model to correlate rotenone intake, SARM1 induction and subsequent motor deficits 103
- Fig. 59.** (A) Schematic representation of rotenone treatment of 1-day old flies for 10-days followed by withdrawal and further experiments were performed at the time points indicated. (B) Survival curve of control adult flies and flies exposed for 10-days to 200 μ M of rotenone and subsequent transfer of these flies to normal media. Fly viability was scored over a period of 40-days using a minimum of 100 flies per treatment. (C) Negative geotaxis assay of adult flies exposed to rotenone as indicated above for 10-days and experiment performed at day-20 post-exposure. (D) *dSarm* expression was analysed at day 20 of flies treated above and results compared to age-matched untreated control flies. *p < 0.05, **p < 0.01 and ***p < 0.001 compared to control flies 103
- Fig. 60.** (A) Survival curve of control adult flies and flies exposed to 200 μ M of rotenone in the presence or absence of the ROS scavenger N-acetyl cysteine or NAC (1 mg/ml). Fly viability was scored over a period of 30-days, using a minimum of 100 flies per treatment. (B) Negative geotaxis assay of the flies at 10-days post-exposure. (C) ROS generation assay in 1-day old flies exposed to 200 μ M

rotenone for 10-days in the presence or absence of NAC. (D) Survival curve of control adult flies and flies exposed to 360 μM of Arsenic (As) along with NAC (1 mg/ml). Fly viability was scored over a period of 30-days, using a minimum of 100 flies per treatment. (E) Negative geotaxis assay of the flies exposed to As in the presence or absence of NAC at 10-days post-exposure. * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$ compared to control flies 104

Fig. 61. Real-time PCR analysis of 1-, 10- and 20-day old flies, exposed to 200 μM of rotenone. (A) *Pink1*, (B) *Atg3* and (C) *Atg5* genes were analysed. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample 106

Fig. 62. Real-time PCR analysis of 1- and 20-day old flies, exposed to 200 μM of rotenone. (A) *nAChRbeta 3* and (B) *EAAT* genes were analysed. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample 106

Fig. 63. (A) Real-time PCR analysis of 1-, 10- and 20-day old flies, exposed to 200 μM of rotenone. *Nrx-1* gene was analysed. Results are representative of at least three independent experiments. (B) Representative western blot analysis of Synapsin and Syntaxin in 20-day old flies exposed to 200 μM rotenone. Tubulin served as a loading control and data was compared with age-matched untreated control flies (n = 3). * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample 107

Fig. 64. Real-time PCR analysis of 1- and 20-day old flies, exposed to 200 μM of rotenone. (A) *hsp70* and (B) *p120* genes were analysed. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample 108

Fig. 65. *Eiger* expression in (A) younger (1-day old) flies exposed to 200 μM of rotenone for 1-day, 10-days, 20-days, and 30-days and (B) aged (20-days old) flies to 200 μM of rotenone for 3-days and 5-days post-treatment. (C) Expression of *Relish* in 1-day old flies exposed to 200 μM of rotenone for 1-day and 10-days. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample 109

Fig. 66. (A) Schematic representation of rotenone treatment of 1-day and 10-day old flies followed by withdrawal in 10 days and further experiments were performed at the time points indicated. (B-E) Real-time PCR analysis of young and aged flies, exposed to 200

μM of rotenone. *Upd1* (B) ,2 (C) ,3 (D) and *Wnt1* (E) expression in younger (1-day old) flies exposed to 200 μM of rotenone and aged (10-days old) flies to 200 μM of rotenone. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample

109

Fig. 67. (A) Survival curve of 1-day old flies exposed to 200 μM of rotenone in the presence or absence of 1 μM of resveratrol. Fly viability was scored over a period of 20-days, using a minimum of 100 flies per treatment. (B) Negative geotaxis assay of the same samples at 10-days post-exposure. (C, D) Real-time PCR analysis of fly heads as treated above. Both (C) *Ect4* and (D) *Eiger* genes were analysed in the 1-day old flies following 1-day post-exposure to rotenone (200 μM) in the presence or absence of resveratrol (1 μM) and results compared to age-matched untreated control flies. (E-G) Real-time PCR analysis of fly heads as treated above. (E) *TotM*, (F) *Tep1* and (G) *Tep2* genes were analysed in the 1-day old flies following 1-day post-exposure to rotenone (200 μM) in the presence or absence of resveratrol (1 μM) and results compared to age-matched untreated control flies. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample

111

Fig. 68. (A, B) Real-time PCR analysis of fly heads. Both (A) *Sir2* and (B) *Ampk* genes were analysed in the flies following exposure to rotenone (200 μM) in the presence or absence of resveratrol (1 μM). Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample

112

Fig. 69. (A, B) Survival curve of 1-day old flies exposed to 100 μM (A) and 200 μM (B) of rotenone in the presence or absence of 1 mM of NR. Fly viability was scored over a period of 30-days, using a minimum of 100 flies per treatment. (C-D) Negative geotaxis assay of the flies exposed to (C) 200 μM and (D) 100 μM of rotenone in the presence or absence of 1 mM of NR. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample

113

Fig. 70. Real-time PCR analysis of fly heads. *dSarm*, *Eiger* and *Relish* genes were analysed in the (A) 1-day and (B) 10-days old flies following exposure to rotenone (100 μM) in the presence or absence of NR (1 μM). Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample

114

- Fig. 71.** Negative geotaxis assay of the 20-days old flies exposed to (A) 100 μ M and (B) 200 μ M of rotenone in the presence or absence of 1 mM of NR. (C) Survival curve of NR pre-treated 10-days old flies exposed to 200 μ M of rotenone in the presence or absence of 1 mM of NR. Fly viability was scored over a period of 30-days, using a minimum of 100 flies per treatment. (D) Negative geotaxis assay of the same samples. Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample 115
- Fig. 72.** Real-time PCR analysis of fly heads. (A) *dSarm* and (B) *Eiger* genes were analysed in the 20-days old flies following exposure to rotenone (100 μ M) in the presence or absence of NR (1 μ M). Results are representative of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared to control sample 115
- Fig. 73.** Proposed model for the study. Exposure to rotenone (pesticide) stimulates production of *Eiger* in the brain milieu of *w¹¹¹⁸* flies that further mediates the increased expression of the *Ect4* or *dSarm* (NADase) from dopaminergic neurons. This, in turn, induces the rapid loss of these neurons that ultimately leads to severe motor deficits and loss of survival. Presence of the anti-inflammatory molecule resveratrol or the NAD⁺ supplement NR can partially reverse rotenone-induced neurotoxicity 121

List of Tables

Table 1.	Sequences of primers used in this study	15
Table 2.	Composition of a typical 50 μ l of digestion mixture	20
Table 3.	Composition of a typical 20 μ l of ligation mixture	21
Table 4.	Sequences of primers used in this study	25
Table 5.	List of primary and secondary antibodies used in this study	29
Table 6.	Alignment results of three domains of <i>C.elegans</i> and human SARM1 protein	33
Table 7.	Sequences of primers used in this study	64
Table 8.	List of primary and secondary antibodies used in this study	66
Table 9.	Sequences of primers used in this study	94
Table 10.	List of primary and secondary antibodies used in this study	96